Ciclopirox nail lacquer solution 8% in the 21st century.

Ciclopirox nail lacquer solution 8% has been shown to be effective in the treatment of dermatophyte onychomycosis of mild to moderate severity Other studies report the effectiveness of ciclopirox nail lacquer in onychomycosis caused by Candida sp and nondermatophyte molds. Ciclopirox nail lacquer may also be valuable in the treatment of early cases of reinfection/relapse. Ciclopirox nail lacquer solution 8% may be an important adjunct to oral antifungal therapy in certain presentations that might be poorly responsive to oral antifungal therapy alone (eg, lateral onychomycosis, longitudinal spike, dermatophytoma, and extensive onycholysis). In some cases, surgical therapies may need to be considered in addition to, or in preference to, topical nail lacquer treatment. The use of ciclopirox nail lacquer solution 8% as an adjunct to oral antifungal therapy may widen the spectrum of activity of the combination because of the broad spectrum of coverage provided by the lacquer. The use of combination therapy may be synergistic in terms of efficacy, enabling a reduction in the duration and cumulative dosage of oral therapy. This could result in a decrease in the frequency and severity of systemic adverse effects associated with the oral antimycotics and the need to be vigilant about drug interactions. Studies need to be conducted to determine the place of combination oral and topical lacquer therapy in the management of onychomycosis.

[1]  A. Rachlis,et al.  Epidemiology and prevalence of onychomycosis in HIV‐positive individuals , 2000, International journal of dermatology.

[2]  M. Bohn,et al.  Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. , 2000, Journal of the American Academy of Dermatology.

[3]  Aditya K. Gupta,et al.  Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. , 2000, Journal of the American Academy of Dermatology.

[4]  R. Summerbell,et al.  Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. , 2000, Journal of the American Academy of Dermatology.

[5]  N. Shear,et al.  A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis , 2000, Drug safety.

[6]  H. Degreef,et al.  Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. , 1999, European journal of dermatology : EJD.

[7]  R. Summerbell,et al.  Combined distal and lateral subungual and white superficial onychomycosis in the toenails. , 1999, Journal of the American Academy of Dermatology.

[8]  J. Sommadossi HIV protease inhibitors: pharmacologic and metabolic distinctions. , 1999, AIDS.

[9]  N. Shear,et al.  The new oral antifungal agents for onychomycosis of the toenails , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  J. Weinberg,et al.  Proximal white subungual onychomycosis in the immunocompetent patient: report of two cases and review of the literature. , 1999, Acta dermato-venereologica.

[11]  S. Shuster Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis , 1999, Springer Berlin Heidelberg.

[12]  A. Markus Hydroxy-Pyridones Outstanding Biological Properties , 1999 .

[13]  S. Nolting Open Studies of Ciclopirox Nail Lacquer in Onychomycosis—A Review , 1999 .

[14]  B. Piraccini,et al.  "Endonyx" onychomycosis: a new modality of nail invasion by dermatophytes. , 1999, Acta dermato-venereologica.

[15]  C. R. Daniel,et al.  Factors that may affect the response of onychomycosis to oral antifungal therapy , 1998, The Australasian journal of dermatology.

[16]  R. Summerbell,et al.  Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey , 1998, The British journal of dermatology.

[17]  C. R. Daniel,et al.  Onychomycosis: strategies to reduce failure and recurrence. , 1998, Cutis.

[18]  B. Piraccini,et al.  Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.

[19]  B. Piraccini,et al.  The prevalence of skin diseases in human immunodeficiency infection and its relationship to the degree of immunosuppression. , 1998 .

[20]  P. Routledge,et al.  Important Drug-Drug Interactions in the Elderly , 1998, Drugs & aging.

[21]  B. Piraccini,et al.  Are local and systemic conditions important for the development of onychomycosis? , 1998, European journal of dermatology : EJD.

[22]  Roberts,et al.  Subungual dermatophytoma complicating dermatophyte onychomycosis , 1998, The British journal of dermatology.

[23]  J. Stover,et al.  Projecting the impact of AIDS on mortality. , 1998, AIDS.

[24]  R. Summerbell,et al.  Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada ‐ a multicenter survey of 2001 patients , 1997, International journal of dermatology.

[25]  G. Cunningham Adverse Drug Reactions in the Elderly and Their Prevention , 1997, Scottish medical journal.

[26]  R. Baran Proximal subungual candida onychomycosis. An unusual manifestation of chronic muco‐cutaneous candidosis , 1997, The British journal of dermatology.

[27]  A. Gupta,et al.  Oral antifungal drug interactions. , 1997, Dermatologic clinics.

[28]  B. Piraccini,et al.  Uncommon clinical patterns of Fusarium nail infection: report of three cases , 1997, The British journal of dermatology.

[29]  M. Ghannoum Future of antimycotic therapy , 1997 .

[30]  B. Piraccini,et al.  Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals , 1996, The British journal of dermatology.

[31]  A. Tosti,et al.  Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. , 1996, Journal of the American Academy of Dermatology.

[32]  M. Baixench,et al.  Onychomycose à Fusarium. , 1996 .

[33]  R. Baran,et al.  Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. , 1996, Acta dermato-venereologica.

[34]  I. Effendy,et al.  Nail incorporation kinetics of terbinafine in onychomycosis patients , 1995, Clinical and experimental dermatology.

[35]  A. Polak‐Wyss Mechanism of action of antifungals and combination therapy , 1995 .

[36]  N. Shear,et al.  Antifungal agents: an overview. Part II. , 1994, Journal of the American Academy of Dermatology.

[37]  I. James,et al.  Short‐duration therapy with terbinafine 1% cream in dermatophyte skin infections , 1994, The British journal of dermatology.

[38]  N. Shear,et al.  Antifungal agents : an overview. II , 1994 .

[39]  M. Ciampini,et al.  Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder * , 1992, Mycoses (Berlin).

[40]  R. Helms Implications of Population Growth on Prevalence of Diabetes: A Look at the Future , 1992, Diabetes Care.

[41]  H. Degreef,et al.  Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.

[42]  K. Weismann,et al.  White nails in AIDS/ARC due to Trichophyton rubrum infection , 1988, Clinical and experimental dermatology.

[43]  N. Noppakun,et al.  Proximal White Subungual Onychomycosis in a Patient with Acquired Immune Deficiency Syndrome , 1986, International journal of dermatology.

[44]  M. Magenheim Pathways to the future. Florida's response to the geriatric imperative. , 1986, Clinics in Geriatric Medicine.

[45]  R. Negroni,et al.  Prophylaxis of tinea pedis interdigitalis with bifonazole, 1% powder. , 1984, Dermatologica.

[46]  Mary P. Eenglish NAILS AND FUNGI , 1976 .

[47]  J. Knox,et al.  Tolnaftate powder in prophylaxis of tinea pedis. , 1974, Southern medical journal (Birmingham, Ala. Print).

[48]  R. Atkinson,et al.  An improved method for the isolation of fungi in onychomycosis , 1973, The British journal of dermatology.